WASHINGTON, Jan. 14, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment in a new sub-study of its Beat ...
AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...
- 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML - - 52% CRc (14 of 27 pts) observed in AUGMENT ...
– Promising clinical activity and deep responses observed with 67% (29/43) CR rate, 88% (38/43) ORR, and 100% (37/37) MRD negativity among responders – – Enrollment underway in pivotal Ph 3 EVOLVE-2 ...
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best biotech stocks to invest in now. On June 12, Syndax Pharmaceuticals announced that data from the BEAT AML trial involving revumenib were ...
DOVER, Del., June 11, 2024 /PRNewswire/ -- Eilean Therapeutics AU Pty Ltd, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule ...
The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD. At the 30th European ...
BOSTON, Jan. 14, 2026 /PRNewswire/ -- AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results